Diabetes, Obesity & Metabolism最新文献

{"title":"The 'awareness effect': A crucial, un-modelleld economic benefit of national type 1 diabetes screening.","authors":"Andrea Enzo Scaramuzza, Valentino Cherubini","doi":"10.1111/dom.70184","DOIUrl":"https://doi.org/10.1111/dom.70184","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between accelerometer-measured physical activity, genetic risk, and incident type 2 diabetes: A prospective cohort study.","authors":"Yang Pan, Wenya Zhang, Yiwen Dai, Yuling Liu, Darui Gao, Yanyu Zhang, Jingya Ma, Menghan Zhu, Xuyang Diao, XinQing Yang, Mengmeng Ji, Wuxiang Xie, Fanfan Zheng","doi":"10.1111/dom.70166","DOIUrl":"https://doi.org/10.1111/dom.70166","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the dose-response relationship between the time spent on different types of physical activity and incident type 2 diabetes (T2D), and whether genetic risk would modify this relationship.</p><p><strong>Materials and methods: </strong>Based on data from 93,096 participants without T2D at baseline from the UK Biobank, we calculated hazard ratios (HRs) between accelerometer-measured physical activity, including sedentary behaviour (SB), sleep, including light-intensity physical activity (LIPA), and moderate-to-vigorous physical activity (MVPA), and the risk of developing T2D by using an isotemporal substitution model. The genetic risk of T2D was measured using standard polygenic risk scores (PRS) calculated by the UK Biobank database.</p><p><strong>Results: </strong>Replacing 1 h/day of SB with other behaviours was associated with a 3% to 38% lower risk of T2D. Replacing 1 h/day of MVPA from other behaviours was associated with a 34% to 38% lower risk of T2D. These inverse associations remained consistent after stratification analyses according to T2D PRS. Among participants within the same genetic risk stratum, diminished MVPA engagement was associated with progressively weaker protection against T2D development. Interestingly, participants with intermediate genetic risk and high levels of MVPA showed a similar risk of T2D compared to those with low genetic risk and low levels of MVPA. Participants with high genetic risk and high levels of MVPA also showed comparable risk to those with intermediate genetic risk and low levels of MVPA.</p><p><strong>Conclusions: </strong>Replacing other physical activities (SB, sleep, and LIPA) with MVPA was associated with a lower risk of T2D, and a high level of MVPA could partially mitigate the genetic risk, suggesting the considerable health benefits driven by a physically active lifestyle.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contributions of intermittently scanned continuous glucose monitoring frequency and bolus insulin dosing on time in range: Analysis of data from CGM and connected insulin pens.","authors":"Pratik Choudhary, Kalvin Kao, Farhan Quadri, Elemer Balogh, Jody Foster","doi":"10.1111/dom.70165","DOIUrl":"https://doi.org/10.1111/dom.70165","url":null,"abstract":"<p><strong>Background and aims: </strong>Integration of data from continuous glucose monitoring (CGM) and connected insulin pens allows us to investigate their use to optimise glucose control. This study examines how insulin bolus frequency reported by connected pens and frequency of glucose scans by an intermittently-scanned continuous glucose monitoring (isCGM) system relate to glycaemic control in a population of real-world European users.</p><p><strong>Methods: </strong>Data from glucose sensors and connected insulin pens were aggregated for LibreView users who integrated their connected pen by January 1, 2024. The most recent 90-day window with ≥30 days' glucose data and ≥15 days of insulin bolus doses following their integration date was analysed. We stratified users by categories of average isCGM scan frequency: low (<6.1 scans/day), medium (6.1-14.0 scans/day) or high (>14.0 scans/day), and average bolus frequency: low (<3.1 boluses/day), medium (3.1-6.7 boluses/day) or high (>6.7 boluses/day).</p><p><strong>Results: </strong>Data from 10,993 users was available over 80.6 days/user. Median scans/day were 9.3 [6.1-14.0] and median bolus/day was 4.5 [3.1-6.7]. Increased daily scans were associated with greater time in range (TIR) 70-180 mg/dL (3.9-10.0 mmol/L) within each of the low, medium, and high bolus frequency groups. Increased bolus frequency was associated with increased TIR in the lowest scanning frequency group. Similar outcomes were observed for time above range (TAR) and glycaemic variability.</p><p><strong>Conclusions: </strong>While glucose monitoring frequency and insulin bolus dosing are both indicators of engagement with diabetes self-management, higher TIR has a closer association with increased rates of user engagement with isCGM than with increased rates of bolus dosing.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-conception weight loss interventions in women with polycystic ovary syndrome and the effect on perinatal outcomes: A quantitative synthesis of surrogate outcomes.","authors":"Amelia Fernandes, Adrienne Gordon, Arianne Sweeting","doi":"10.1111/dom.70116","DOIUrl":"https://doi.org/10.1111/dom.70116","url":null,"abstract":"<p><strong>Aims: </strong>Polycystic ovary syndrome (PCOS) guidelines recommend weight optimisation to improve anthropometric, metabolic and androgenic complications, but data is lacking for pregnancy outcomes.</p><p><strong>Materials and methods: </strong>We aimed to assess which weight loss interventions improve pregnancy outcomes for women with PCOS and overweight or obesity. A systematic search of Embase, Medline (Ovid) and the Cochrane Clinical Trials Registry for English language articles from database inception until 22 July 2024 was conducted. We included weight loss intervention randomised controlled trials (RCTs) for women with PCOS and body mass index (BMI) ≥25 kg/m². Primary outcomes were pregnancy rates, live births and miscarriages. Secondary outcomes were anthropometric, androgenic, metabolic and other perinatal complications.</p><p><strong>Results: </strong>Of 9010 articles, 7077 abstracts were screened and 37 RCTs included. One study reported increased pregnancy rates with a 12-month lifestyle intervention versus standard care (23.3%-26.7% vs. 16.7%) (low certainty) but no difference in live birth rate, time to conception or antenatal outcomes. Lifestyle interventions reduced BMI by -0.34 kg/m² (-0.65 to -0.02) on quantitative meta-analysis. Limitations include outcome measure heterogeneity, intervention heterogeneity, inconsistent definitions and low use of core outcome sets.</p><p><strong>Conclusions: </strong>Limited data on antenatal outcomes highlight a knowledge gap amongst a group at high perinatal risk.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145204939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tryptophan derivatives as non-invasive diagnostic indicators for obesity-related MASLD in children and adolescents.","authors":"Shumin Zhan, Xingyun Wang, Chen Wang, Bowen Zhu, Jianfang Gao, Zhou Peng, Rui Wang, Yun Yang, Liang Zhang, Tengfei Wang, Jiaoxiang Wu, Wei Wu, Ke Huang, Guanping Dong, Qiannan Ren, Shan Wang, Senjie Wang, Xuelian Zhou, Liling Xu, Junfen Fu, Xirong Guo","doi":"10.1111/dom.70162","DOIUrl":"https://doi.org/10.1111/dom.70162","url":null,"abstract":"<p><strong>Aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a major health burden in children and adolescents with obesity. This study aimed to characterize metabolic alterations associated with obesity-related MASLD and to evaluate the potential of tryptophan (TRP)-derived metabolites as non-invasive biomarkers for early diagnosis.</p><p><strong>Materials and methods: </strong>A total of 30 normal-weight individuals and 80 patients diagnosed with obesity were included in the discovery cohort. Circulating metabolites were quantified and compared among normal-weight individuals, patients with obesity, and those with obesity-related MASLD to identify metabolic changes associated with disease status. In vitro experiments using mouse hepatocytes and liver organoids were conducted to assess the effects of TRP-derived metabolites on intracellular lipid accumulation. Finally, a non-invasive diagnostic model was developed using machine learning techniques and validated in an independent cohort of 112 individuals.</p><p><strong>Results: </strong>Circulating TRP metabolism was markedly elevated in children and adolescents with obesity-related MASLD compared with both normal-weight controls and individuals with simple obesity. TRP-derived metabolites significantly promoted intracellular lipid accumulation in mouse hepatocytes and liver organoids via the induction of oxidative stress. The non-invasive diagnostic model based on TRP-derived metabolites demonstrated robust performance in differentiating obesity-related MASLD from simple obesity in both the discovery and validation cohorts.</p><p><strong>Discussion: </strong>These findings highlight the pivotal role of TRP metabolism in the pathogenesis of MASLD in children and adolescents with obesity. Elevated TRP-derived metabolites may contribute to hepatic lipid accumulation through oxidative stress and serve as promising non-invasive biomarkers for the early diagnosis of obesity-related MASLD. The machine learning-based diagnostic model offers a practical and less invasive alternative to current diagnostic approaches such as liver biopsy.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.","authors":"Guy W Neff","doi":"10.1111/dom.70148","DOIUrl":"https://doi.org/10.1111/dom.70148","url":null,"abstract":"<p><p>Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, which include the regulation of amino acid metabolism via a liver-pancreatic alpha cell axis, stimulation of lipolysis and mitochondrial fat oxidation in the liver (and possibly in other tissues), reduction of caloric intake, and an increase in energy expenditure (at least in animal models). These advances in basic science-together with clinical trials that found GCGR antagonists increased body weight, hepatic fat, and serum lipids in people with type 2 diabetes-are driving the development of GCGR-based agonists for the treatment of obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and other cardio-kidney-metabolic diseases. Due to the hyperglycaemic effects of glucagon, these unimolecular compounds also incorporate moieties that activate the glucagon-like peptide-1 (GLP-1) receptor, which stimulates insulin secretion to lower blood glucose levels. In early clinical trials, several GCGR-based multi-agonists (mazdutide, survodutide [being developed by the sponsor of this review], retatrutide) demonstrated substantial efficacy for eliciting weight loss in people with obesity while improving liver health in those with MASLD. However, the physiological and molecular pathways modulated by chronic pharmacological activation of the GCGR in humans remain to be delineated, as do its potential risks. Thus, there is great interest in the ongoing phase 3 clinical trials of these compounds. As data for their safety and efficacy emerge, glucagon's role in energy regulation and lipid metabolism will become clearer, along with warranting a potential new therapeutic option for obesity and MASLD.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine.","authors":"Sara Russo, Luca Proto, Manoel Galvao Neto, Giulia Angelini, Samantha Pezzica, Fabrizia Carli, Elena Previti, Maria Emiliana Caristo, Vincenzo Bove, Rima Chakaroun, Sara Roggiani, Valentina Tremaroli, Carel W Le Roux, Stefan R Bornstein, Amalia Gastaldelli, Ivo Boskoski, Geltrude Mingrone","doi":"10.1111/dom.70167","DOIUrl":"10.1111/dom.70167","url":null,"abstract":"<p><strong>Aims: </strong>This study evaluated the metabolic efficacy of ForePass-a novel, incision-free, reversible, endoscopically delivered device that mimics biliopancreatic diversion-in growing pigs. The primary aim was the superiority of ForePass over Semaglutide in improving insulin sensitivity (S_I). Secondary aims included effects on weight gain, endogenous glucose production (EGP), disposition index (DI), oral glucose rate of appearance, plasma metabolomics, and faecal microbiota.</p><p><strong>Materials and methods: </strong>Over 30 days, 12 young Landrace pigs (46.7 ± 1.1 kg) received ForePass, twice-weekly Semaglutide, or sham endoscopy. Sample size was calculated a priori for the primary endpoint (Δ = 0.6 min^-1·pM^-1, SD = 0.3, α = 0.05, 80% power), yielding n = 4 per group. Body weight was monitored, and oral glucose tolerance testing (OGTT) with stable isotope tracers assessed hepatic glucose disposal. S_I, insulin secretion, glucose rate of appearance (R_a), metabolomics, and faecal microbiota were analysed.</p><p><strong>Results: </strong>ForePass improved S_I more than Semaglutide (2.75 ± 0.37 vs. 1.34 ± 0.21 min^-1·pM^-1) and sham (0.78 ± 0.46; p <0.05). Weight gain was 2.0 kg (4%) with ForePass, versus 16.3 kg (36%) with Semaglutide and 21.1 kg (47%) with sham (p <0.0001). Semaglutide reduced weight gain by 11% versus sham (p <0.05). DI was 2.6-fold higher with ForePass than Semaglutide and 3.5-fold higher than sham. ForePass reduced oral glucose R_a by 40% versus Semaglutide and 30% versus sham, while EGP 46% was lower than Semaglutide and 51% lower than sham (p <0.0001). Metabolomics showed ForePass increased ketogenic and branched-chain amino acids, whereas Semaglutide raised lactate and alanine. Only ForePass increased faecal Akkermansia muciniphila.</p><p><strong>Conclusions: </strong>ForePass produced superior insulin sensitivity and weight outcomes versus Semaglutide. Its distinct effects on glucose disposal, metabolomics, and microbiota support development as a reversible, incision-free endoscopic therapy that may bridge the gap between pharmacological and surgical options for obesity and type 2 diabetes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all-cause mortality, in patients with steatotic liver disease.","authors":"Weronika Stupalkowska, Alexander Henney, Eric G Sheu, Uazman Alam, Daniel J Cuthbertson","doi":"10.1111/dom.70173","DOIUrl":"https://doi.org/10.1111/dom.70173","url":null,"abstract":"<p><strong>Aim: </strong>Metabolic bariatric surgery (MBS) improves histological endpoints in steatotic liver disease (SLD), but data on longer-term clinical outcomes in this population are scarce. Here, we assessed the impact of MBS on hepatic and extrahepatic morbidity and mortality in individuals with SLD.</p><p><strong>Methods: </strong>Patients with SLD, with/without a history of MBS (MBS/no-MBS cohorts, respectively) between 01/01/2004 and 31/10/2019, were identified using the TriNetX platform. Cohorts were balanced with propensity score matching (PSM). Maximum follow-up was set to 5 years. The primary outcome was a composite of major adverse liver outcomes (MALO): cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant. Secondary outcomes included major cardiovascular (MACE) and kidney (MAKE) adverse events, obesity-associated cancers, and all-cause mortality (ACM). We performed sub-group analyses according to sex, MBS type, and risk factors (BMI ≥50 kg/m² and type 2 diabetes (T2D)).</p><p><strong>Results: </strong>We identified 15,262 and 540,031 patients (for the MBS and no-MBS cohorts, respectively); 14,970 patients/cohort after PSM (mean age: 46.7 vs. 47.4; female: 74.3% vs. 75.7%; mean follow-up, 4.1 years). MBS was associated with reduced HR of MALO (0.84, 95% CI 0.75-0.95), MACE (0.52, CI 0.47-0.57), MAKE (0.54, CI 0.41-0.72), obesity-related cancers (0.58, CI 0.50-0.67), and ACM (0.49, 0.43-0.56). In subgroup analyses, MBS was associated with reduced HR of MALO, MACE, MAKE, obesity-related cancers, and ACM in females, patients with T2D, BMI > 50 kg/m² and irrespective of surgery type.</p><p><strong>Conclusion: </strong>In patients with SLD, MBS is associated with significant reductions in the rates of adverse hepatic and extrahepatic outcomes and all-cause mortality over 4 years' follow-up.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.","authors":"Sergio Di Molfetta, Ludovico Di Gioia, Irene Caruso, Mariangela Caporusso, Paolo Trerotoli, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino","doi":"10.1111/dom.70150","DOIUrl":"https://doi.org/10.1111/dom.70150","url":null,"abstract":"<p><strong>Aims: </strong>To provide an updated analysis of the performance of different hybrid closed loop (HCL) systems in randomised controlled trials (RCTs) on subjects with type 1 diabetes.</p><p><strong>Materials and methods: </strong>We conducted a systematic review with meta-analysis. We searched four online databases and performed hand-searching of conference proceedings to find studies from inception to 18 April 2025. We included RCTs enrolling subjects with type 1 diabetes, evaluating commercial HCL systems against other insulin therapy regimens, with a duration of intervention ≥2 weeks, and reporting time in range (TIR) as an outcome. Studies involving pregnant women were excluded.</p><p><strong>Results: </strong>A total of 37 studies evaluating seven different HCL systems (CamAPS Fx, Control IQ, DBLG1, iLet BP, MiniMed 670G, MiniMed 780G, and Omnipod 5) were included. In studies with a mean age < 18 years, mean TIR was 64.1% (95% CI: 61-67.2), ranging from 59.3% (95% CI: 49.6-69.1) with MiniMed 780G to 68% (95% CI: 65.8-70.3) with Control IQ, and end-of-study HbA1c was 7.4% (95% CI: 7-7.7), ranging from 6.7% (95% CI: 6.6-6.9) with CamAPS Fx to 7.9% (95% CI: 6.9-9) with MiniMed 780G. In studies with a mean age ≥ 18 years, mean TIR was 70.8% (95% CI: 68.6-73), ranging from 63.1% (95% CI: 59.4-66.8) with Omnipod 5 to 74.4% (95% CI: 69.7-79.1) with MiniMed 780G, and end-of-study HbA1c was 7.1% (95% CI: 7-7.3), ranging from 7.0% (95% CI: 6.9-7.1) with Control IQ to 7.2% (95% CI: 7-7.5) with MiniMed 670G.</p><p><strong>Conclusions: </strong>In RCTs, commercial HCL systems show different achievements of CGM metrics and HbA1c in people with type 1 diabetes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1-based therapies, the stepwise trap, and missed surgical windows: A policy perspective on delayed access to bariatric surgery.","authors":"Kuo-Feng Hsu","doi":"10.1111/dom.70163","DOIUrl":"https://doi.org/10.1111/dom.70163","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}